Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment

Published:2023-03 Issue:1 Volume:55 Page:760-765
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Pan Ya-ru¹,Liu Si-qi¹,He Yi-shan¹,Xue Yuan¹²,Wang Jian³,Huang Rui³,Wu Chao³,Lu Jian-chun¹²,Liu Long-gen¹²

Affiliation:

1. Changzhou Clinical Medical College, Nanjing Medical University, Changzhou, Jiangsu Province, China

2. Institute of Hepatology, The Third People’s Hospital of Changzhou, Changzhou, Jiangsu Province, China

3. Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province, China

Funder

the 333 High-level Talents Project of Jiangsu Province

the Science and Technology Project of Changzhou

Qingnian Project of Changzhou Health Commission

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2023.2177725

Reference24 articles.

1. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

2. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ

3. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy

4. First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide

5. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3